Abstract
Salvage chemotherapy has been used by some oncology centres for patients with residual malignant or immature elements in retroperitoneal lymph node dissections removed for metastatic non-seminomatous germ cell tumours. However, surveillance of these patients shows that many are cured by surgery alone. 118 retroperitoneal lymph node dissections for metastatic non-seminomatous germ cell tumours were reviewed and the morphology seen within them was quantified. 28 of these had immature or malignant elements and had been treated by surveillance before administration of further chemotherapy. The proliferation rate in these cases was assessed by immunochemistry. The proliferation index and the amount of embryonal carcinoma (EC) were both predictors of recurrence and therefore the need for further chemotherapy. Patients with greater than 25% of EC had an 84% chance of relapse and those with a Ki-67 index of greater than 50% had a 71% chance of relapse. The two tests had a positive predictive value of 83% and 71%, respectively. Patients with such a high risk of recurrence could be considered for post-operative adjuvant therapy at this point whilst others would be suitable for a watchful waiting approach. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Albers P, Miller GA, Orazi A, Ulbright TM, Albers J, Donohue JP and Foster RS (1995) Immunohistochemical assessment of tumour proliferation and volume of embryonal carcinoma identify patients with clinical stage A seminomatous testicular germ cell tumor at low risk for occult metastasis. Cancer 75: 844–850
Albers P, Bierhoff E, Neu D, Fimmers R, Wernert N and Muller SC (1997) MIB-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumours predicts patients at low risk for metastasis. Cancer 79: 1710–1716
Albers P, Ganz A, Hannig E, Miersch WE and Muller SC (2000) Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol 164: 381–384
Aprikian AG, Herr HW, Bajorin DF and Bosl GJ (1994) Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. Cancer 74: 1329–1334
Eid H, Gulyas M, Geczi L, Bodrogi I, Institoris E and Bak M (1998) Expression of bcl-2 in testicular carcinoma: correlation with tumor progression and MDR1/Pgp. Cancer 83: 331–336
Einhorn LH, Williams SD, Mandelbaum I and Donohue JP (1981) Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction. Cancer 48: 904–908
Fernandez EB, Sesterhenn IA, McCarthy WF, Mostofi FK and Moul JW (1994) Proliferating cell nuclear antigen expression to predict occult disease in clinical stage 1 nonseminomatous testicular germ cell tumours. J Urol 152: 1133–1138
Fizazi K, Tjulandin S, Salvioni R, Ragan D, Bokemeyer C, Gerl A, De Bono JS, Flechon A, De Giorgi U, Kerbrat P, Geoffrois L, Bower M, Mahe C, Bouzy J, Bulanov A, Pizzocaro G, Hartmann JT, Nichols C, Schmoll HJ, Fossa S and Droz JP (1999) Viable malignant cells after primary chemotherapy for metastatic non-seminomatous germ cell tumours (NSGCT): results from an international study. Proc ASCO 18: 308a
Fox EP, Weathers TD, Williams SD, Loehrer PJ, Ulbright TM, Donohue JP and Einhorn LH (1993) Outcome analysis for patients with persistent nonteratomatous germ cell tumor inpost chemotherapy retroperitoneal lymph node dissections. J Clin Oncol 11: 1294–1299
Heidenreich A and Moul JW (1997) Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I nonseminomatous germ cell tumors. J Urol 158: 620–625
Heidenreich A, Sesterhenn IA, Mostofi FK and Moul JW (1998) Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumours at low risk and high risk for metastasis. Cancer 83: 1002–1011
Herr HW (1997) Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer?. Br J Urol 80: 653–657
Hines J, Rustin G, Newlands E and Christmas TJ (1997) The prognostic significance of malignant tissue removed at retroperitoneal lymph node dissection after chemotherapy in metastatic testis cancer. Br J Urol 79: 21
International Germ Cell Cancer Collaborative Group (1997) International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15: 594–603
Javadpour N and Young JD (1986) Prognostic factors in non-seminomatous testicular cancer. J Urol 135: 497–499
Key G, Becker MHG, Duchrow M, Schluter C, Askaa J and Gerdes C (1991) Immunobiochemical and molecular biologic characterisation of the cell proliferation associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Path 138: 867–873
Leonardi E, Girlando S, Serio G, Mauri FA, Perrone G, Scamoni S, Dalla Palma P and Barbareschi M (1992) PCNA and Ki-67 expression in breast carcinoma: correlation with clinical and biological variables. J Clin Path 45: 416–419
Little JS, Foster RS, Ulbright TM and Donohue JP (1994) Unusual neoplasms detected in testis cancer patients undergoing post-chemotherapy retroperitoneal lymphadenectomy. J Urol 152: 1144–1149
Loehrer PJ Sr, Gronin R, Nichols CR, Weathers T and Einhorn LH (1998) Vinblastine plus ifossfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumour. J Clin Oncol 16: 2500–2504
Michael H, Lucia J, Foster RS and Ulbright TM (2000) The pathology of late recurrence of testicular germ cell tumours. Am J Surg Path 24: 257–273
Pizzocaro G, Nicolai N, Milani A, Piva L, Merson M, Colavita M and Salvioni R (1998) Is further chemotherapy necessary in radically resected residual cancer in non-seminomatous germ cell tumors (NSGCT) of the testis following induction chemotherapy?. Proc ASCO 17: 309a
Ravi R, Oliver RTD, Ong J, Badenoch DF, Fowler CG, Paris AMI and Hendry WF (1997) A single centre observational study of surgery and late malignant events after chemotherapy for germ cell cancer. Br J Urol 80: 647–652
Richie JP and Kantoff PW (1991) Is adjuvant chemotherapy necessary for patients with stage B1 testicular cancer?. J Clin Oncol 9: 1393–1396
Shamash J, Oliver RTD, Ong J, Raja M, Edmonds P, Gallagher CJ, Ostrowski J, LeVay J and Williams M (1999) 60% salvage rate for germ cell tumours using sequential m-BOP, surgery and ifosfamide based chemotherapy. Ann Oncol 10: 685–692
Statin P, Damber J-E, Kalber GL and Bergh A (1997) Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer. J Urol 157: 219–222
Stenning SP, Parkinson MC, Fisher C, Mead GM, Cook PA, Fossa SD, Horwich A, Jones WG, Newlands ES, Oliver RTD, Stenwig AE and Wilkinson P (1998) Postchemotherapy residual masses in germ cell tumor patients. Cancer 83: 1409–1419
Steyerberg EW, Keizer HJ, Fossa SD, Sleijfer DTH, Toner GC, Schraffordt Koops H, Mulders PFA, Messemer JE, Ney K, Donohue JP, Bajorin D, Stoter G, Bosl GJ and Habbema JDF (1995) Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data form six study groups. J Clin Oncol 13: 1177–1187
Tait D, Peckham MJ, Hendry WF and Goldstraw P (1984) Post-chemotherapy surgery in advanced non-seminomatous germ cell testicular tumours: the significance of histology with particular reference to differentiated (mature) teratoma. Br J Cancer 50: 601–609
Toner GC, Panicek DM, Heelan RT, Gellere NL, Lin S-Y, Bajorin D, Motzer RJ, Scher HI, Herr HW, Morse MJ, Fair WR, Sogani PC, Whitmore WF, McCormack PM, Bains MS, Martini N and Bosl GJ (1990) Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 8: 1683–1694
Williams SD, Stablein DM, Einhorn LH, Muggia FM, Weiss RB, Donohue JP, Paulson DF, Brunner KW, Jacobs EM, Spaulding JT, DeWys WD and Crawford ED (1997) Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 317: 1433–1438
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Berney, D., Shamash, J., Hendry, W. et al. Prediction of relapse after lymph node dissection for germ cell tumours: can salvage chemotherapy be avoided?. Br J Cancer 84, 340–343 (2001). https://doi.org/10.1054/bjoc.2000.1613
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1613
Keywords
This article is cited by
-
Metastasierte testikul�re Keimzelltumoren
Der Onkologe (2005)
-
DNA topoisomerase I and II expression in drug resistantgerm cell tumours
British Journal of Cancer (2002)